{'fraction_non_alphanumeric': 0.03064066852367688, 'fraction_numerical': 0.001392757660167131, 'mean_word_length': 5.913461538461538, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor

Pyoderma gangrenosum (PG) is a rare, solitary or multiple, chronically progressive, painful, destructive, sterile neutrophil inflammation of unexplained aetiology and pathogenesis, which often remains resistant to treatment. An autoimmunological and autoinflammatory genesis is discussed, which is the main reason why there are so many immunosupressant therapies available. PG may occur in association with inflammatory and haematological disorders, such as Crohn's disease, myeloma, leukaemia, lymphoma and polycythemia vera (PV), as it is the case in our patient presented here. This article is protected by copyright. All rights reserved.